Back to discover

Protein / target

Beta-nerve growth factor

Encoded byNGFP01138Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
Small-molecule tractable
Druggability
Druggable Family
3
Research papers

Protein at a glance

Biological role

Metalloendopeptidase inhibitor

Strongest disease association

Hypertension

Via encoding gene NGF · Genetic evidence · score 0.86

Therapeutic position

Established drug target

Antibodies

Research activity

Emerging research

3 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems.

View complete UniProt function annotation

Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems (PubMed:14976160, PubMed:20978020). Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (Probable) (PubMed:20978020). The immature NGF precursor (proNGF) functions as a ligand for the heterodimeric receptor formed by SORCS2 and NGFR, and activates cellular signaling cascades that lead to inactivation of RAC1 and/or RAC2, reorganization of the actin cytoskeleton and neuronal growth cone collapse. In contrast to mature NGF, the precursor form (proNGF) promotes neuronal apoptosis (in vitro) (By similarity). Inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI (PubMed:20164177). Binds lysophosphatidylinositol and lysophosphatidylserine between the two chains of the homodimer. The lipid-bound form promotes histamine relase from mast cells, contrary to the lipid-free form (By similarity)

Subcellular location

SecretedEndosome lumen
Domains and Gene Ontology detail (26)

Gene Ontology

  • Ccytosol
  • Cendosome lumen
  • Cextracellular region
  • Cextracellular space
  • CGolgi lumen
  • Csynaptic vesicle
  • Fgrowth factor activity
  • Flipid binding
  • Fmetalloendopeptidase inhibitor activity
  • Fnerve growth factor receptor binding
  • Ftransmembrane receptor protein tyrosine kinase activator activity
  • Pcell surface receptor protein tyrosine kinase signaling pathway

241 aa · 27 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Receptor tyrosine kinase signallingGOSynaptic signallingGOCell proliferation & survivalGO
View supporting evidence

Receptor tyrosine kinase signalling

  • ·transmembrane receptor protein tyrosine kinase activator activity
  • ·cell surface receptor protein tyrosine kinase signaling pathway

Synaptic signalling

  • ·modulation of chemical synaptic transmission

Cell proliferation & survival

  • ·negative regulation of cell population proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene NGF

Gene-level evidence surfaced through the gene NGFthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Osteoarthritis, Knee
0.87Well supported

Genetic evidence dominant · Open Targets 0.55

Hypertension
0.86Well supported

Genetic evidence dominant · Open Targets 0.53

Angina Pectoris
0.81Well supported

Genetic evidence dominant · Open Targets 0.49

Osteoarthritis
0.80Well supported

Genetic evidence dominant · Open Targets 0.50

Osteoarthritis, Hip
0.79Well supported

Genetic evidence dominant · Open Targets 0.49

View evidence synthesis (5)
Osteoarthritis, KneeWell supported
0.87
agreement 0.760.97
Genetic61%Clinical37%Literature2%

Open Targets aggregate 0.55 · 3 independent evidence families

HypertensionWell supported
0.86
agreement 0.721.00
Genetic96%Literature4%

Open Targets aggregate 0.53 · 2 independent evidence families

Angina PectorisWell supported
0.81
agreement 0.670.95
Genetic98%Literature2%

Open Targets aggregate 0.49 · 2 independent evidence families

OsteoarthritisWell supported
0.80
agreement 0.690.90
Genetic47%Clinical45%Literature8%

Open Targets aggregate 0.50 · 3 independent evidence families

Osteoarthritis, HipWell supported
0.79
agreement 0.690.90
Genetic68%Clinical31%Literature1%

Open Targets aggregate 0.49 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Osteoarthritis, Knee0.55
Hypertension0.53
Osteoarthritis0.50
Angina Pectoris0.49
Osteoarthritis, Hip0.49
Essential Hypertension0.48
Coronary Artery Disease0.48

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (5)
TANEZUMABApproval
FULRANUMABPhase 3
FASINUMABPhase 3
MEDI-578Phase 1
PG-110Phase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (druggable family) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Advanced Clinical and UniProt loc high conf support this modality.

Protein degradersEmerging

Feasibility evidence (small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Druggable FamilyAB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

3 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.